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ABSTRACT
Objective: to investigate the perception of harms and benefits associated with cannabis use among adolescents 
and how regulatory changes might affect their intention to use marijuana. 
Method: this multi-centric cross-sectional survey study. participants included 2717 students aged 15–17 from 
10 cities in Belize, Brazil, Chile, Colombia, Dominican Republic, Jamaica, Mexico, St. Kitts and Nevis, and 
Trinidad and Tobago. 
Results: an average lifetime prevalence of cannabis use of 30.6% (25.8% past year, 15.8% past 30 days). 
Most participants reported that their closest friends use cannabis (60%); many (55%) stated that they would 
not use marijuana, even if it were legally available. 
Conclusion: statistics revealed that a strong perception of benefits, a low perception of risk, and friends’ use 
of cannabis were associated with individual use as well as intention to use within a hypothetical context of 
regulatory change.
DESCRIPTORS: Adolescent behavior. Cannabis. Risk factors. Government Regulation.
PERCEPCIÓN DE DAÑOS Y BENEFICIOS DEL USO DE CANNABIS ENTRE 
ADOLESCENTES DE AMÉRICA LATINA Y CARIBE
RESUMEN
Objetivo: investigar la percepción de daños y beneficios asociados al uso de marihuana en adolescentes y 
cómo los cambios regulatorios pueden afectar la intención de uso. 
Método: estudio multicéntrico, cuantitativo y transversal tipo encuesta. los participantes fueron 2,717 
estudiantes entre 15 y 17 años de 10 ciudades de Belice, Brasil. Chile, Colombia, República Dominicana, 
Jamaica, México, San Cristóbal y Nieves, y Trinidad y Tobago. 
Resultados: prevalencia de alguna vez en la vida de 30.6% (25.8% ultimo año, 15.8% últimos 30 días). Los 
adolescentes refieren que amigos cercanos consumen marihuana (60%). Los participantes (55%) declaran 
que no usarían marihuana, incluso si estuviera disponible legalmente. 
Conclusión: las estadísticas revelan que la alta percepción de los beneficios, baja percepción de daño 
y amigos que consumen marihuana, está asociado con el consumo y la intención de uso en el contexto 
hipotético de cambios regulatorios.
DESCRIPTORES: Conducta del adolescente. Cannabis. Factores de riesgo. Regulación gubernamental.
PERCEPÇÃO DE DANOS E BENEFÍCIOS DO USO DE CANNABIS ENTRE 
ADOLESCENTES DA AMÉRICA LATINA E CARIBE
RESUMO
Objetivo: investigar a percepção de danos e benefícios associados ao uso de maconha entre os adolescentes 
e como as mudanças regulatórias podem afetar a intenção de usar maconha. 
Método: estudo multicêntrico de corte transversal. Os participantes foram 2.717 alunos com idades entre 15 
e 17 anos de 10 cidades em Belize, Brasil, Chile, Colômbia, República Dominicana, Jamaica, México, São 
Cristóvão e Nevis e Trinidad e Tobago. 
Resultados: prevalência de uso de maconha na vida de 30,6% (25,8% no ano passado,15,8% nos últimos 
30 dias). Os participantes relataram que os amigos mais próximos usam maconha (60%); e metade (55%) 
afirmou que não usariam maconha, mesmo se ela estivesse legalmente disponível. 
Conclusão: as estatísticas revelaram que percepção elevada de benefícios, percepção de baixo risco e uso 
de maconha por parte de amigos estavam associados ao uso individual, bem como à intenção de usar a 
maconha em um contexto hipotético de mudanças regulatórias.
DESCRITORES: Comportamento do adolescente. Cannabis. Fatores de risco. Regulamentação 
governamental.
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INTRODUCTION
Regulatory changes on cannabis use in several countries have proved to be an ongoing 
struggle for global health policies. It is possible that such changes may have considerable effects 
on adolescents’ perception of harm regarding cannabis use.1 In most Latin American and Caribbean 
countries, the prevalence of cannabis use among secondary school students is increasing.2 Some 
evidence suggests that decreased risk perception and increased availability explain the trend of 
increasing cannabis consumption among adolescents.3–4 Studies have reported that when the perception 
of risk declines, the use of cannabis increases and vice versa.5–6 Adolescents who perceived cannabis 
use as involving less risk were twice as likely to use marijuana.7
The 2014 World Drug Report stated that declining risk perception and increased availability 
may lead to increases in adolescent use of marijuana. It also stated that among adolescents and 
young adults, more permissive cannabis regulations correlate with a decrease in the perceived risk 
of use, and that lowered risk perception has been found to predict increase in use. Additionally, it 
reported that although the general public may perceive cannabis to be the least harmful illicit drug, the 
proportion of total treatment admissions for cannabis increased in several countries from 2003–2012.4
The 2013 U.S. survey Monitoring the Future6 reported that perceptions of the risks associated 
with cannabis use have shifted so that fewer adolescents believe that drugs are harmful. Such a 
change may predict increased future use of a drug. The survey found that only 41.7% of eighth-
graders see occasional cannabis use as harmful, while 66.9% see regular use as harmful. This 
was the lowest level documented in this age group since 1991, when the study began tracking risk 
perception among eighth-graders. Perceived risk associated with cannabis use continued to decline 
sharply in all three grades surveyed. The 2013 survey also found that disapproval of cannabis use 
had declined somewhat, which may lead to future increases in cannabis use. Perceived availability 
has remained relatively stable. Cannabis use among twelfth-graders was found to be more prevalent 
than smoking cigarettes (21.4% versus 19.2% past month). 
Another study reported that perceived risk was higher among nonusers of cannabis than 
among those who reported cannabis use.8 Among cannabis users, risk perception was not influenced 
by the frequency of cannabis use, nor was it influenced by the actual experience of a drug-related 
consequence. Among abstainers, perceived risk and the potential consequences of cannabis use may 
serve a protective role against the initiation of cannabis use. For those who use marijuana, intervention 
efforts utilizing motivation enhancement approaches could explore the discrepancy between perceived 
risks and actual experienced consequences.8
The average age of first cannabis use ranges from 12-15 years in different countries, and has 
an inverse relationship with the perception of related harms among adolescents.6 Several studies 
have found that the most common onset of drug use occurs during the passage from childhood to 
adolescence, either as experimentation, occasional use, abuse, or misuse.9–10 
Onset of cannabis use among adolescents is of particular concern due to the increased 
risk of harm to this age group.4 Some of these concerns include the use of other drugs and drug 
dependency,11–12 a risk of heavy dependency,13 lung and respiratory problems,14–15 memory and 
attention impairments,12,15–21 a decrease in cognitive capacity related to the process of learning, 
such as attention, concentration, ranking, visual-spatial integration, immediate retention, and visual 
memory,21–22 psychosocial development problems and mental health problems,23–24 poorer cognitive 
performance associated with early initiation and persistent use between the early teenage years and 
adulthood,4,23–25 and an increase in car accidents associated with acute cannabis use.26–30
The evidence about potential harms of cannabis use is not conclusive and inconsistencies 
appear among studies. The relationship between cannabis use by adolescents and psychosocial harm 
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is likely to be multifaceted, which might explain such inconsistencies. For example, one study suggested 
that long-term mental deficits may be reversible and remain subtle rather than disabling once a person 
abstains from use.31–32 Moreover, the actual mechanisms underlying the effects of cannabis on the 
cardiovascular and cerebrovascular systems are complex and not fully understood.12 Furthermore, it is 
difficult to establish a linear causality between cannabis and mental health because factors other than 
cannabis use might be associated with the risk of mental illness.12 Despite some contentious discussions 
regarding its harm, cannabis use in adolescence appears to have several effects, both short-term and 
long-term, on different aspects of life, and could affect development and life in adulthood.
Other studies have focused on the medical benefits of cannabis use. Cannabis has been 
used for a wide spectrum of medical purposes to treat symptoms and illnesses, including chronic 
pain,12,33–35 nausea,36–37 epilepsy,38–39 and individuals with AIDS40 and patients with cancer.41–42 These 
positive effects of cannabis use are relevant in the context of debates regarding the establishment 
of new regulations to legalize medical and recreational uses, but it is still important to consider how 
cannabis affects adolescent health.
Overall, it is important to assess how adolescents perceive the adverse effects and/or benefits 
of cannabis use, as well as their intention to use marijuana, within the context of global discussions 
on regulatory changes. This paper presents the results of a multi-centric and multi-national research 
study by the CICAD/CAMH Capacity Building Program43, which explored these issues in Belize, Brazil, 
Chile, Colombia, Dominican Republic, Jamaica, Mexico, St. Kitts and Nevis, and Trinidad and Tobago. 
The goal of this study was to investigate how adolescents’ perceptions of harm and benefits 
are related to cannabis use, and how regulatory changes might be affecting intentions about cannabis 
use in these countries.
METHOD
This study was a multi-centric, quantitative cross-sectional survey conducted in Belize, Brazil, 
Chile, Colombia, Dominican Republic, Jamaica, Mexico, St. Kitts and Nevis, and Trinidad and Tobago. 
The general objective was to explore the association between perceptions of harms and benefits and 
cannabis use among students aged 15-17 years. Specific objectives were: a) to describe prevalence 
by total sample, gender, and site, proportion of friends that use marijuana, general perception of harms, 
attitudes about cannabis legalization, and use and intention to use; b) to investigate any association 
between friends’ use of cannabis and cannabis use; c) to explore attitudes about regulatory changes 
and intention to use; and d) to explore associations between harms, benefits, friends’ drug use, and 
intention to use.
The extent and context to which cannabis is legalized, de-penalized, or decriminalized are 
important issues in Latin America and the Caribbean (Table 1). Most of the countries included in this 
study prohibit the recreational and medicinal use, sale, and production of marijuana. Some are now 
beginning to explore changes to the regulatory process, while others have already explored and passed 
de-penalization or decriminalization laws. To date, none of the nine countries have legalized marijuana.3
Participants were 2717 public secondary school students (57% female and 43% male), aged 
15-17 years (M=15.92 SD=0.77), from 10 cities within the nine countries (Table 2). Due to differences 
in class streaming and grade levels across the nine countries, sample selection was based on age 
rather than grade.
Legalization and/or decriminalization of cannabis have implications that are difficult to predict, 
so countries will only discover the effects after some time of monitoring, evaluation, and assessment 
of these regulatory changes. To date, no studies have explored the effects of legislative changes on 
individuals and society, especially on adolescents. To address this research gap, this study investigated 
the perception of harms and benefits associated with cannabis use among adolescents within four 
Caribbean and five Latin American countries.
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Table 1 – Current (2016) cannabis regulations in participating 
Caribbean and Latin America countries.
Country Regulation of Marijuana Notes
Belize Decriminalized One can possess up to 10 grams of marijuana for personal, recreational or medical use.
Brazil De-penalized
For unauthorized possession, individuals must complete a 
safety measure such as drug abuse education or community 
service. Sale and production are illegal.
Chile Decriminalized Consumption or possession in public places is sanctioned. A judge decides minimum quantity for possession.
Colombia Decriminalized No more than 20 grams for personal use.
Dominican Republic Illegal Some discussion about decriminalization.
Jamaica Decriminalized
Quantities not exceeding 2 ounces (56.6 grams) or cultivation 
of five or fewer plants for personal use became decriminalized 
in 2015.44
Mexico Decriminalized When quantities do not exceed 5 grams sanctions are not applied.
St. Kitts & Nevis Illegal Current and ongoing discussion about decriminalization.
Trinidad & Tobago Illegal Current and ongoing discussion about decriminalization
Adapted from Inter-American Drug Abuse Control Commission.3 





Belize City - Belize 273 10.0 16.0
Brasilia - Brazil 268 9.9 15.9
Viña del Mar - Chile 268 9.9 15.9
Concepcion - Chile 268 9.9 16.0
Bogota - Colombia 268 9.9 15.9
Santo Domingo - Dominican Republic 268 9.9 15.9
Manchester - Jamaica 300 11.0 15.9
Mexicali - Mexico 268 9.9 16.1
Basseterre - St. Kitts & Nevis 268 9.9 15.7
Saint Joseph - Trinidad & Tobago 268 9.9 15.7
A sample size of 268 in each city will have a medium effect size at a α=0.05 level.45
The questionnaire used to collect data was an amalgam of scales taken from three instruments: 
(a) Inter-American Drug Use Data System (SIDUC) Secondary Students School Survey;2 (b) Monitoring 
the Future (MTF);6 and (c) the Benthin Risk Perception Measure46. The questionnaire included 23 
items that explored demographic variables (sex, age, and grade – 3 items), cannabis use and age 
at onset (3 items), friends’ use of cannabis (4 items), perception of harms (11 items), perception of 
medical and recreational cannabis use (1 item), and intention to use cannabis in the future (1 item).
Cannabis use was measured using items from the Inter-American Drug Use Data System 
Secondary School Student Survey – SIDUC.2 Lifetime cannabis use was assessed using a binary 
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response (yes, no). Measures of past 12 months and past 30 days use were assessed using six 
response categories (ranging from no use to use every day), but were reduced to binary for analysis 
purposes (use or non-use). Students were asked how old they were when they used cannabis for 
the first time. 
Friends’ use of cannabis was investigated by asking respondents how many of their closest 
friends use marijuana. Response choices were: none, some, about half of my friends, all of my 
friends, and don’t know. Three items from Monitoring the Future6 explored a general perception of 
harm related to using cannabis once or twice, occasionally, and regularly. Responses were provided 
on a five-point scale (no risk, slight risk, moderate risk, great risk, don’t know).
Some items from the Benthin Risk Perception Measure46 were used to explore perception of 
harm. This measure uses a seven-point scale to assess the perceived risks and benefits of various 
behaviours. It has been used widely in studies exploring perception of risk, harms, and benefits, most 
of which have reported Cronbach alphas over 0.70.47–49 A Spanish version is available and has been 
previously used in Latin America.50 This study used a slightly modified version with 11 questions: 
8 items from the original scale and 3 additional items. Risk of harm items from the original scale 
assessed knowledge, fear, personal risk, risk to peers, peer influence, and avoidability. Perception of 
benefit items from the original scale included benefits versus risk as well as admiration (social), with 
new items added for emotion (“In your opinion, to what extent can smoking cannabis help persons in 
your age group to cope with their emotional difficulties?”), health (“In your opinion, to what extent can 
smoking cannabis improve physical wellbeing among persons in your age group?”), and academic 
performance (“In your opinion, to what extent does smoking cannabis improve academic performance?”). 
An overall average of risk and benefits was calculated, where higher scores reflected greater risk.51 
The frequency of each response option was also calculated. A moderate internal consistency for the 
total scale (Cronbach’s alpha=.73) and the benefits subscale (Cronbach’s alpha=.74) was found. A 
lower internal consistency was obtained for the harm subscale (Cronbach’s alpha=.54). 
Opinion about medical use versus recreational use of cannabis was examined using a question 
with a five-point scale (cannabis should not be used at all, be used for medical purposes, be used for 
recreational purposes, be used for medical and recreational purposes, don’t know). Finally, participants 
were asked about their intentions to use cannabis within the context of regulatory changes. The 
question asked: “If you were 18 years of age and cannabis was legal, which of the following would 
you most likely do?” This question was based on a similar question from the Monitoring the Future 
survey6. The six-category response options were: not use it even if it were legally available, try it, use 
it about as often as do now, use it more often, and use it less often. 
Data gathering was divided into two phases: pretesting and administration of the instrument. 
In the first phase, the instrument was translated into two languages (Spanish and Portuguese). 
Researchers at each site performed a pre-test with secondary school populations similar to those 
required for this study. Administration of the instrument started with collection of informed consent 
from all subjects. Participation was voluntary, and confidentiality was maintained at all times. The 
questionnaire was administered using paper and pencil in a classroom/room at the selected school. 
Data were analyzed using descriptive and inferential statistics. Descriptive statistics were 
used to describe demographic data and address research questions on prevalence, and inferential 
analyses were used to explore relationships. 
A researcher in each city obtained approval for the study from the relevant ethics authorities at 
the National Drug Council, local department of education and the school board, and from the ethical 
committees at each affiliated institution. Next, active consent was obtained from parents and students.
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RESULTS
The results revealed an average overall lifetime prevalence of cannabis use of 30.6% (male=35%, 
female=28%), 25.8% for past year (male=29%, female=23%), and 15.8% for the past 30 days 
(male=19%, female=13%). Prevalence was significantly higher among males than females (life time 
X2(1)=16.49, p<0.001; past year X2(1)=11.34, p<0.001; and past month X2(1)=14.93, p<0.001). The 
average overall age of onset was 12 years (SD=4.37). Table 3 lists the prevalence of use by site.
Overall, 40% of all participants reported that none of their closest friends use cannabis or 
do not know, while 60% stated that at least some of their closest friends use it (43.2% some of their 
friends, 12% about half of their friends, 5% all of their friends). An association was observed between 
past year prevalence and friends’ use of cannabis (X2(1)=260.72, p<0.001). A vast majority (96%) of 
participants that used cannabis during the past 12 months had at least some friends that use marijuana.
With regard to risk perception, the majority (73%) stated that there is no or a slight risk of using 
cannabis once or twice, while 50% felt that occasional use involved moderate or high risk; most felt 
that regular use involved either moderate (23%) or high risk (50%).
A logistic regression was performed to analyze the association between lifetime, past year, 
and past month prevalence of cannabis use and the perception of harms and benefits, evaluated with 
the Benthin measure. A high score represented a low perception of harm and a strong perception 
of benefits. Friends’ use of cannabis was also included in the model. Interactions between harms, 
benefits, and gender were evaluated, and a binary logistic regression was conducted for each category 
of prevalence. The results revealed that perceptions of harms and benefits, and having friends that 
use marijuana, were significantly associated with lifetime (R2.=.22 Nagelkerke; Χ2(2)=616.75, p<0.001), 
past year (R2=.33 Nagelkerke; Χ2(2)=588.63, p<0.001), and past month prevalence (R2=.28 Nagelkerke; 
Χ2(2)=414.63, p<0.001). None of the models revealed a significant interaction with gender. 
These results demonstrated significant associations between cannabis use and three variables: 
a lower perception of harms, a stronger perception of benefits, and having friends that use cannabis 
(Table 4). As shown in Table 3, having at least one friend that uses cannabis was more strongly 
associated with cannabis use than the perception of harms and benefits. Therefore, friends’ use of 
drugs is a powerful predictor of cannabis use in this sample. 
Attitudes about cannabis legalization and the intention to use at 18 years (the age of majority 
in the 10 sites is 18 years old) in a hypothetical context of legalization were also explored. The results 
revealed that attitudes about medical and recreational use of cannabis were generally favourable. 
On average, 42% of participants (45% female, 39% male) felt that cannabis should be used only for 
medical purposes and 28% (26% female, 31% male) felt that cannabis should be use for medical and 
recreational purposes. In contrast, 19% of participants (21% female, 17% male) felt that cannabis 
should not be used at all, even if it were legal. Only 3% (2% female, 4% male) felt that it should be 
used only for recreational purposes, and 8% (6% female, 9% male) were not sure. 
To explore intention to use cannabis in a hypothetical context of regulatory changes, participants 
were asked what they would do if they were 18 years of age and cannabis was legal. As shown in 
Table 5, 55,1% of participants stated that they would not use marijuana, even if it were legally available; 
20,6% said they would try it, and 15,7% said they would continue using it.
The associations between harms, benefits, friends’ use of marijuana, and intention to use 
in a hypothetical context of regulatory changes were explored using a logistic regression analysis. 
The results revealed significant associations with intention to use (R2=.37 Nagelkerke; Χ2(2)=668.55, 
p<0.001). A strong perception of benefits, a low perception of risk, and having friends that use cannabis 
were all associated with intention to use in a hypothetical context of regulatory changes (p<0.001). 
Additionally, friends’ use of drugs had a stronger effect than perceived harms and benefits.
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DISCUSSION
The ten sites are located in nine countries that are at different stages in terms of regulatory 
changes with regard to cannabis use.3 Interestingly, a comparison of the prevalence of cannabis use 
at each study site by regulation status revealed no relationship between the prevalence of reported 
use and regulation status. In other words, the fact that cannabis use is illegal is not linearly and directly 
related to a low prevalence of use. However, it is difficult to draw definitive conclusions in this regard, 
because of possible influences of many variables, such as socio-political, legal, and historical factors 
in each nation, which were not addressed in this study.
Table 3 – Cannabis use prevalence by site, 2015. (n=2717) 
Site
Percentage
Lifetime Past Year Past Month
Belize City - Belize 41.4 39.2 24.9
Brasilia - Brazil 23.5 19.0 9.7
Viña del Mar - Chile 52.2 47.8 32.8
Concepcion - Chile 46.1 38.8 24.6
Bogota - Colombia 31.3 22.6 10.8
Santo Domingo - Dominican Republic 5.6 4.9 3.4
Manchester - Jamaica 29.3 21.9 11.5
Mexicali - Mexico 13.8 9.0 3.0
Basseterre - St. Kitts & Nevis 30.7 26.1 17.3
Saint Joseph - Trinidad & Tobago 32.6 28.5 20.2
Table 4 – Association between perception of harms, benefits, and 
friends’ use of cannabis and cannabis use, 2015. (N=2717)
Perception
Lifetime prevalence Past year prevalence Past month prevalence
OR OR OR
Low perception of harm 1.61* 1.62† 1.66†
Strong perception of benefits 1.58* 1.75† 1.81*
Friends use of marijuana 9.35† 8.53† 8.93†
*p<0.01; †p<0.001
Table 5 – Intention to use cannabis in a hypothetical context of regulatory changes, 2015. (n=2717)
If you were 18 years of age and cannabis was legal, which of the 
following would you most likely do?
Percentage
Total Male Female
Not use it, even if it were legally available 55.1 51.6 57.7
Try it 20.6 21.01 20.3
Use it about as often as I do now 8.3 10.5 6.6
Use it more often than I do now 6.5 7.5 5.8
Use it less than I do now 1.9 2.0 1.8
Don’t know 7.6 7.3 7.8
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Consistent with the literature review, the results of this study revealed that prevalence rates of 
adolescent cannabis use are significantly higher among males than females, and that average age 
of onset was 12 years, consistent with the range of 12-15 years reported in previous research.6 The 
overall prevalence rate (M=30.6%) was relatively high, but rates varied greatly by study site, from 
5.6% lifetime use in Santo Domingo to 52.2% lifetime use in Viña del Mar. 
The results also revealed that the majority of participants (73%) felt there is no risk in using 
cannabis once or twice. Nonusers perceived the risk to be higher than users did, so perceived risk 
appears to prevent nonusers from trying the drug. 
The influence of friends that use drugs was a more powerful predictor than any other variable, 
so having friends who use drugs is an important risk factor for cannabis use during adolescence. This 
finding is consistent with previous research indicating that an adolescent’s peer network serves as a 
strong risk factor for both initiation (from ages 11-15) and progression to regular use of marijuana.49–52 
This finding is of tremendous relevance and must be taken into account when developing prevention 
policies. Peers can promote negative attitudes, but also positive attitudes about health and healthy 
behaviours; in other words, peer influence can also be a protective factor.53
The generally favourable attitudes among participants about medical and recreational were 
not surprising. Previous research has found that adolescents perceive cannabis as the illicit drug 
causing the least harm,1 which is consistent with general trends in the Western world toward increased 
tolerance of cannabis use and less prohibition.
Interestingly, even if participants viewed cannabis use favourably, this does not mean that they 
intended to use it if it were legally available. The majority (55%) reported no intention to use, while the 
results were less clear among those who are already using marijuana. Some said they would continue 
using it, some would use it more, and some would use it less. Only 21% of the sample reported that 
they would try cannabis if it were legal, which means that regulatory changes would probably lead 
to a slight increase in cannabis experimentation among youth in Latin America and the Caribbean. 
Given that the mean lifetime use was 30.5%, intention to use in the future is not particularly high. 
However, intention to use cannabis was assessed in a hypothetical context, so these results should 
be interpreted with caution. 
One limitation of the study is that the findings cannot be generalized to the participating 
countries because of the convenience sample selection. Moreover, the cross-sectional design means 
that causality cannot be inferred from the results. Another weakness of the research is related to 
the complex nature of drug use among adolescents, which involves many risk factors within various 
domains that we did not address: our focus was only on the perceived harms and benefits of cannabis 
use. We assessed intended cannabis use within a hypothetical context of regulatory changes, so 
the results might not accurately predict future behaviour. Finally, the non-uniformity in regulatory 
frameworks across the participating countries may have influenced the analysis when the data were 
merged and compared among the sites. Nevertheless, the findings can inform current public policy 
debates and will be useful for educational purposes.
Non-prohibitionist approaches to cannabis regulation have emerged only recently, so the 
potential adverse effects and benefits of various aspects of legal regulation are not known.47 This 
study tried to address the considerable knowledge gap about how regulatory changes might affect 
adolescent behaviour. Very few studies have explored how legislative changes regarding cannabis 
use might affect individuals and society, and to the best of our knowledge, no previous study has 
explored this topic among adolescents. 
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CONCLUSION
This study explored associations between perceived harms and benefits and cannabis use 
among students aged 15–17 years in ten study sites within Latin America and the Caribbean. The 
results revealed considerable heterogeneity in the prevalence of cannabis use among the sites, and a 
high prevalence of cannabis use in the total sample. The prevalence of cannabis use was significantly 
higher among males than females. The majority of participants perceived no risk in occasional use of 
marijuana, and half of the sample considered regular use to involve a high level of risk. 
Half of the participants also said they would not use marijuana, even if it were legally available. 
Many students who had favourable attitudes about cannabis use reported no intention to use it if it were 
legally available, but 21% said they would use it in the future, if it were legally available. Significant 
associations were found between harms, benefits, friends’ drug use, and intention to use. 
In conclusion, the high prevalence rates suggest the need to implement interventions aimed 
at preventing cannabis use among adolescents. It is not realistic to prevent drug experimentation, 
but perhaps initiation can be delayed.
Finally, the unprecedented shifts in regulatory policies regarding drug use provide opportunities 
to discuss and address the harms and limitations of strict prohibition policies. More research is needed 
to critically examine regulatory frameworks and how they affect health, especially among vulnerable 
populations such as children and adolescents.
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